Detailed imaging and genetic analysis reveal a secondary BRAF(L) (505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

Marlous Hoogstraat, Christa G Gadellaa-van Hooijdonk, Inge Ubink, Nicolle J M Besselink, Mark Pieterse, Wouter Veldhuis, Marijn van Stralen, Eelco F J Meijer, Stefan M Willems, Michael A Hadders, Thomas Kuilman, Oscar Krijgsman, Daniel S Peeper, Marco J Koudijs, Edwin Cuppen, Emile E Voest, Martijn P Lolkema

Research output: Contribution to journal/periodicalArticleScientificpeer-review

Fingerprint

Dive into the research topics of 'Detailed imaging and genetic analysis reveal a secondary BRAF(L) (505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences